Advertisement
UK markets close in 2 hours 6 minutes

  • FTSE 100

    7,836.74
    -40.31 (-0.51%)
     

  • FTSE 250

    19,321.72
    -128.95 (-0.66%)
     

  • AIM

    743.03
    -2.26 (-0.30%)
     

  • GBP/EUR

    1.1678
    -0.0005 (-0.05%)
     

  • GBP/USD

    1.2458
    +0.0020 (+0.16%)
     

  • Bitcoin GBP

    52,004.41
    +1,933.20 (+3.86%)
     

  • CMC Crypto 200

    1,333.65
    +21.03 (+1.63%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CRUDE OIL

    82.17
    -0.56 (-0.68%)
     

  • GOLD FUTURES

    2,391.00
    -7.00 (-0.29%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,734.16
    -103.24 (-0.58%)
     

  • CAC 40

    8,020.85
    -2.41 (-0.03%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Ultimovacs ASA – New share capital registered

Ultimovacs ASA
·1-min read

Oslo, Norway, 2 November 2021

Reference is made to the stock exchange announcement published by Ultimovacs ASA (the "Company") on 27 October 2021 regarding the successful placing of a private placement with gross proceeds of NOK 270 million (the "Private Placement").

The share capital increase related to Private Placement has been registered with the Norwegian Register of Business Enterprises. Following such registration, the share capital of the Company is NOK 3,422,176.10 divided into 34,221,761 shares, each with a par value of NOK 0.10.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

ADVERTISEMENT

For additional information, please contact:

Carlos de Sousa, Chief Executive Officer
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92 507

Hans Vassgård Eid, Chief Financial Officer
Email: hans.eid@ultimovacs.com
Phone: +47 482 48 632